prous science
thomson has acquired prous science. prous science’s information solutions help knowledge - based drug discovery and development. the prous science integrity portal is said to provide access to more than 265, 000 compounds with demonstrated biological activity and close to 100, 000 patent family records .
prous science will become part of thomson scientific, the giant electronic media company said thursday .
the prous science award for new technologies in drug discovery 2004 for prof. c. oliver kappe
the average salary for prous science is $ 84, 359 per year, ranging from $ 71, 305 to $ 95, 295. compare more salaries for prous science at paysa. com .
scientists use data from prous science in drug discovery and development work. the prous science integrity web portal provides access to more than 265, 000 compounds, with demonstrated biological activity and close to 100, 000 patent family records .
the deal
signals an excellent opportunity to accelerate our product development and innovation plan in the drug discovery space ,
said j. r. prous, founder and ceo of prous science .
thomson corp. has acquired prous science of barcelona, spain, a supplier of life sciences information to business and professional customers worldwide, for an undisclosed price .
this acquisition really complements our pharma and biotechnology workflow solution offerings. we look forward to working closely with the prous science management team to maximize synergies and add value for our customers .
prous science has built a strong global brand on its flagship solutions, which have been built by scientists for scientists ,
vin caraher, ceo of thomson scientific, said in a release .
by combining the financial strength, creativity and technology of thomson with prous science, we will further drive innovations that help scientists find better solutions to their specific problems while fostering the emergence of new ideas .
prous institute for biomedical research s. a. via augusta 59, office 706 08006 barcelona spain email: info @ urltoken
‘prous science has built a strong global brand on its flagship solutions which have been built by scientists for scientists, ’ said vin caraher, president and ceo, thomson scientific. ‘this acquisition really complements our pharma & biotechnology workflow solution offerings. ’
we are committed to discovering novel therapies for substantially unmet medical needs by applying our expertise in computational science, synthetic chemistry, molecular and cellular biology, and pharmacology. our uniqueness and our core competencies reflect 50 years of experience creating and managing biomedical knowledge .
the european federation for medicinal chemistry (efmc) is an independent association representing medicinal chemistry societies in europe. its objective is to advance the science of medicinal chemistry by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders .
the
prous institute - overton and meyer award for new technologies in drug discovery
was established to encourage innovation and investigation in technologies related to drug discovery. the award is given biennially, without restrictions regarding nationality, to acknowledge the discovery, evaluation or use of a new technology, and consists of a diploma,  7. 500 and an invitation to present a lecture at an efmc - ismc symposium .
html public
- / / w3c / / dtd xhtml 1. 0 transitional / / en
urltoken
all clarivate analytics websites use cookies to improve your online experience. they were placed on your computer when you launched this website. you can change your cookie settings through your browser .
assess the availability of your title for entertainment works in the u. s .
integrity enhances your drug discovery and development research by integrating essential biological, chemical and pharmacological data to support successful drug research and development .
integrity and the integrity – biomarkers module provide the key scientific information and insight needed to prioritize drug development candidates, benchmark competitors / market leaders and assess the competitive landscape earlier than any other drug r & d; database – directly supporting scientific discovery .
integrate biological, chemical and pharmacological data to help drive innovation and support earlier decision - making when developing new hypotheses around targets, drugs, and how to translate animal models into humans .
updated daily, drug information is consolidated into a single, flexible resource to help you stay on top of the latest developments in your field without having to spend time reviewing irrelevant materials .
hard data points – not just references – provide key information from in vitro and in vivo pharmacological assays and pharmacokinetics studies .
gain context for your r & d efforts with disease briefings; these disease - and disorder - specific dynamic summaries on current treatments and future trends in drug therapy include risk factors, prevalence, morbidity, mortality and cost .
avoid costly mistakes and learn from the success of your peers with comprehensive coverage of pipeline, patent, literature & conferences from a scientific perspective .
the integrity – biomarkers module brings an added dimension to integrity by linking drugs, targets and genes to biomarkers information from a diverse range of sources .
drugs of today and drugs of the future offer insight into innovative drugs in early clinical development or nearing commercialization, while drug news provides dynamic drug news and alerts every business day. for more information about these journals, contact us here .
when making decisions about potential prospects it is very important to know what stage of clinical development a compound is in. the further along the development pipeline, the better, as the compound has a greater chance of getting to the market – and of course larger - scale synthesis will be required .
for inquiries related to this message please contact support. for sales inquiries, please visit urltoken
if you believe this to be in error, please confirm below that you are not a robot by clicking
i' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading. for more information you can review the terms of service and cookie policy .
access to clarivate analytics integrity is available to licensed users. to request more information about this product ,
( !) we use cookies to give you the best possible experience on our website. by continuing to browse this site, you give consent for cookies to be used. for more details, please read our cookie policy (! )
the company’s headquarters will remain in barcelona, spain. the company’s more than 180 employees will become part of the pharmaceutical / chemical business unit within thomson scientific .
the subject who is truly loyal to the chief magistrate will neither advise nor submit to arbitrary measures .
thomson corp. , based in toronto and with operational headquarters in stamford, conn. , supplies information and software tools to professionals in the fields of law, tax, accounting, financial services, scientific research and health care .
welcome to the globe and mail’s comment community. this is a space where subscribers can engage with each other and globe staff. non - subscribers can read and sort comments but will not be able to engage with them in any way. click here to subscribe .
if you would like to write a letter to the editor, please forward it to letters @ urltoken. readers can also interact with the globe on facebook and twitter .
welcome to the globe and mail’s comment community. this is a space where subscribers can engage with each other and globe staff .
we aim to create a safe and valuable space for discussion and debate. that means :
due to technical reasons, we have temporarily removed commenting from our articles. we hope to have this fixed soon. thank you for your patience. if you are looking to give feedback on our new site, please send it along to feedback @ urltoken. if you want to write a letter to the editor, please forward to letters @ urltoken .
for further information: for further information: media, allison hagan, + 1 - 215 - 823 - 1881, allison. hagan @ thomson. com, or investors, frank j. golden, vice president, investor relations, + 1 - 203 - 539 - 8470, frank. golden @ thomson. com, both of thomson scientific web site: urltoken urltoken urltoken
browse our custom packages or build your own to meet your unique communications needs .
copyright © 2018 cnw group ltd. all rights reserved. a cision company .
enter your e - mail address to receive an e - mail with your account information .
if you don' t have an account and would like to submit a manuscript, please click here .
warning: the ncbi web site requires javascript to function. more ...
html public
- / / w3c / / dtd xhtml 1. 0 strict / / en
urltoken
previous recipients were: prof. d. neri in 2006 and prof. c. o. kappe in 2004 .
professor neri receives this award for his pioneering work establishing synthetic antibody libraries obtained employing phage display technology. although this technology is still in its early stages, it holds significant potential for the discovery of new lmw binders to variety of protein targets .
the award was granted to prof. c. oliver kappe, karl - franzens university, graz, on the basis of his outstanding scientific curriculum vitae. in particular, his work on microwave - assisted combinatorial chemistry was considered highly innovative and fruitful. the award was presented during the opening session of the xviiith international symposium on medicinal chemistry, on sunday, august 15, in copenhagen, denmark .
this application requires javascript. please turn on javascript in order to use this application.
prous science was an international health science publishing company , established in 1965 and headquartered in barcelona , catalonia , spain . the company was acquired by thomson reuters in 2007 . the prous institute for biomedical research was founded in 2000 by dr josep prous jr as a spinoff biotech company of prous science . dr. j.r. prous was the ceo and president of prous science.its head offices are located in barcelona and it has subsidiaries in philadelphia ( united states ) , buenos aires ( argentina ) and tokyo ( japan ) . its research is based on the use of datamining , statistical analysis and chemoinformatic techniques , a recent and innovative international concept registered under the name " druginformatics " . these techniques are complemented by laboratory methods from combinatorial chemistry , molecular biology and functional genomics . 
prous science was an international health science publishing company, established in 1965 and headquartered in barcelona, catalonia, spain. the company was acquired by thomson reuters in 2007. the prous institute for biomedical research was founded in 2000 by dr josep prous jr as a spinoff biotech company of prous science. dr. j.r. prous was the ceo and president of prous science.its head offices are located in barcelona and it has subsidiaries in philadelphia (united states), buenos aires (argentina) and tokyo (japan). its research is based on the use of datamining, statistical analysis and chemoinformatic techniques, a recent and innovative international concept registered under the name " druginformatics ". these techniques are complemented by laboratory methods from combinatorial chemistry, molecular biology and functional genomics.
prous science was an international health science publishing company, established in 1965 and headquartered in barcelona, catalonia, spain. the company was acquired by thomson reuters in 2007. the prous institute for biomedical research was founded in 2000 by dr josep prous jr as a spinoff biotech company of prous science. dr. j.r. prous was the ceo and president of prous science.its head offices are located in barcelona and it has subsidiaries in philadelphia (united states), buenos aires (argentina) and tokyo (japan). its research is based on the use of datamining, statistical analysis and chemoinformatic techniques, a recent and innovative international concept registered under the name " druginformatics ". these techniques are complemented by laboratory methods from combinatorial chemistry, molecular biology and functional genomics.